Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

This pilot study evaluates a newly developed point-of-care (PoC) device designed to measure bilirubin levels in human blood ...

Gallstone disease is linked to metabolic disorders, such as obesity, diabetes, and metabolic dysfunction-associated steatotic liver disease.